Renalytix Plc
RNLX · NASDAQ
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -32.7% | 14.6% | 99.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 6.8% | 20.6% | 30.9% | 46.1% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,246% | -1,225.8% | -1,774.2% | -2,381.2% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,461.6% | -1,340.2% | -1,524.4% | -2,329% |
| EPS Diluted | -0.62 | -1.1 | -1.34 | -0.98 |
| % Growth | 43.6% | 17.9% | -36.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |